Dimyristoyl lecithin
Imagent (dimyristoyl lecithin) is an unknown pharmaceutical. Dimyristoyl lecithin was first approved as Imagent on 2002-05-31.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dimyristoyl lecithin
+
Perflexane
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| IMAGENT | Vesselon | N-021191 DISCN | 2002-05-31 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
76 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | 2 | — | 11 | ||
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 1 | — | 2 | 5 | 2 | 10 |
| Fissure in ano | D005401 | HP_0012390 | K60.2 | 1 | 2 | 1 | 1 | — | 4 |
| Coronary vasospasm | D003329 | EFO_0004225 | — | — | 1 | 2 | — | 3 | |
| Atrial flutter | D001282 | EFO_0003911 | — | — | — | 2 | — | 2 | |
| Microvascular angina | D017566 | — | — | 1 | 1 | — | 2 | ||
| Stable angina | D060050 | I20.8 | — | — | — | 1 | — | 1 | |
| Percutaneous coronary intervention | D062645 | — | — | — | 1 | — | 1 | ||
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | 1 | |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | — | 1 | — | 1 |
Show 5 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 1 | 1 | — | — | 5 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | 2 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | — | 2 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 1 | — | — | 1 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | 1 | |
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | 1 | 1 | — | — | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | 1 | |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 1 | 1 | — | — | 1 |
| Reperfusion injury | D015427 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | 1 | — | — | — | 1 |
| Myocardial bridging | D054084 | — | 1 | — | — | — | 1 | ||
| Craniotomy | D003399 | 1 | 1 | — | — | — | 1 | ||
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | 3 | — | — | — | — | 3 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Hepatitis c | D006526 | B19.2 | 1 | — | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | — | — | — | 1 |
| Thrombosis | D013927 | 1 | — | — | — | — | 1 | ||
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | 1 | 1 | ||
| Familial primary pulmonary hypertension | D065627 | I27.0 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DIMYRISTOYL LECITHIN |
| INN | perflubron |
| Description | 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine is a 1,2-diacyl-sn-glycero-3-phosphocholine where the two phosphatidyl acyl groups are specified as tetradecanoyl (myristoyl). It has a role as an antigen and a mouse metabolite. It is a 1,2-diacyl-sn-glycero-3-phosphocholine, a phosphatidylcholine 28:0 and a tetradecanoate ester. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 13699-48-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201501 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | Q1D0Q7R4D9 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 838 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15,576 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more